ASBP vs. VXRT, OVID, CNTB, XBIT, ALTS, ATRA, QNCX, ENTX, IRD, and ABOS
Should you be buying Aspire Biopharma stock or one of its competitors? The main competitors of Aspire Biopharma include Vaxart (VXRT), Ovid Therapeutics (OVID), Connect Biopharma (CNTB), XBiotech (XBIT), ALT5 Sigma (ALTS), Atara Biotherapeutics (ATRA), Quince Therapeutics (QNCX), Entera Bio (ENTX), Opus Genetics (IRD), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry.
Aspire Biopharma vs. Its Competitors
Aspire Biopharma (NASDAQ:ASBP) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.
Aspire Biopharma has higher earnings, but lower revenue than Vaxart.
Aspire Biopharma has a net margin of 0.00% compared to Vaxart's net margin of -122.63%. Aspire Biopharma's return on equity of 0.00% beat Vaxart's return on equity.
19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 48.0% of Aspire Biopharma shares are owned by company insiders. Comparatively, 2.8% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Vaxart has a consensus target price of $2.00, indicating a potential upside of 438.21%. Given Vaxart's stronger consensus rating and higher probable upside, analysts plainly believe Vaxart is more favorable than Aspire Biopharma.
Aspire Biopharma has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.
In the previous week, Vaxart had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 4 mentions for Vaxart and 2 mentions for Aspire Biopharma. Aspire Biopharma's average media sentiment score of 0.95 beat Vaxart's score of 0.64 indicating that Aspire Biopharma is being referred to more favorably in the media.
Summary
Vaxart beats Aspire Biopharma on 7 of the 13 factors compared between the two stocks.
Get Aspire Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASBP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aspire Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:ASBP) was last updated on 9/17/2025 by MarketBeat.com Staff
Free ASBP Stock Alerts